Peter Kies - Net Worth and Insider Trading
Peter Kies Net Worth
The estimated net worth of Peter Kies is at least $48,704 dollars as of 2024-12-01. Peter Kies is the CFO of Inovio Pharmaceuticals Inc and owns about 11,274 shares of Inovio Pharmaceuticals Inc (INO) stock worth over $48,704. Details can be seen in Peter Kies's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Peter Kies has not made any transactions after 2021-06-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Peter Kies
Peter Kies Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Peter Kies owns 1 companies in total, including Inovio Pharmaceuticals Inc (INO) .
Click here to see the complete history of Peter Kies’s form 4 insider trades.
Insider Ownership Summary of Peter Kies
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
INO | Inovio Pharmaceuticals Inc | 2021-06-09 | CFO |
Peter Kies Latest Holdings Summary
Peter Kies currently owns a total of 1 stock. Peter Kies owns 11,274 shares of Inovio Pharmaceuticals Inc (INO) as of June 9, 2021, with a value of $48,704.
Latest Holdings of Peter Kies
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
INO | Inovio Pharmaceuticals Inc | 2021-06-09 | 11,274 | 4.32 | 48,704 |
Holding Weightings of Peter Kies
Peter Kies Form 4 Trading Tracker
According to the SEC Form 4 filings, Peter Kies has made a total of 6 transactions in Inovio Pharmaceuticals Inc (INO) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Inovio Pharmaceuticals Inc is the sale of 2,812 shares on June 9, 2021, which brought Peter Kies around $337,838.
Insider Trading History of Peter Kies
- 1
Peter Kies Trading Performance
GuruFocus tracks the stock performance after each of Peter Kies's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Peter Kies is 14.53%. GuruFocus also compares Peter Kies's trading performance to market benchmark return within the same time period. The performance of stocks bought by Peter Kies within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Peter Kies's insider trading performs compared to the benchmark.
Peter Kies Ownership Network
Peter Kies Owned Company Details
What does Inovio Pharmaceuticals Inc do?
Who are the key executives at Inovio Pharmaceuticals Inc?
Peter Kies is the CFO of Inovio Pharmaceuticals Inc. Other key executives at Inovio Pharmaceuticals Inc include Chief Medical Officer Michael John Sumner , Chief Scientific Officer Laurent Humeau , and Chief Operating Officer Jacqueline Elizabeth Shea .
Inovio Pharmaceuticals Inc (INO) Insider Trades Summary
Over the past 18 months, Peter Kies made no insider transaction in Inovio Pharmaceuticals Inc (INO). Other recent insider transactions involving Inovio Pharmaceuticals Inc (INO) include a net sale of 5,700 shares made by Lota S. Zoth ,
In summary, during the past 3 months, insiders sold 0 shares of Inovio Pharmaceuticals Inc (INO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 475 shares of Inovio Pharmaceuticals Inc (INO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 475 shares.
Inovio Pharmaceuticals Inc (INO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Inovio Pharmaceuticals Inc Insider Transactions
Peter Kies Mailing Address
Above is the net worth, insider trading, and ownership report for Peter Kies. Currently GuruFocus does not have mailing address information for Peter Kies.